A5020932026- Glycosylation and Glycoproteins Research
- Cancer, Hypoxia, and Metabolism
- Angiogenesis and VEGF in Cancer
- Axon Guidance and Neuronal Signaling
- Cell Adhesion Molecules Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Microtubule and mitosis dynamics
- Ubiquitin and proteasome pathways
- Neuroendocrine Tumor Research Advances
- Lymphatic System and Diseases
- Proteoglycans and glycosaminoglycans research
- Hedgehog Signaling Pathway Studies
- Peptidase Inhibition and Analysis
- Electron Spin Resonance Studies
- Cancer-related cognitive impairment studies
- Tuberous Sclerosis Complex Research
- Cancer Treatment and Pharmacology
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cancer Genomics and Diagnostics
- Analytical Chemistry and Sensors
- S100 Proteins and Annexins
- Renal cell carcinoma treatment
- Digestive system and related health
- Pancreatitis Pathology and Treatment
- Pancreatic and Hepatic Oncology Research
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2016-2020
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2020
Vita-Salute San Raffaele University
2016-2020
San Raffaele University of Rome
2016-2018
University of Parma
2013
The clinical use of doxorubicin (Doxo), a widely used anticancer chemotherapeutic drug, is limited by dose-dependent cardiotoxicity. We have investigated whether chromogranin A (CgA), cardioregulatory protein released in the blood neuroendocrine system and heart itself, may contribute to regulation cardiotoxic antitumor activities Doxo. effects physiologic dose full-length recombinant CgA on Doxo-induced cardiotoxicity activity were rats using vivo ex models murine melanoma, fibrosarcoma,...
NG2/CSPG4 is a complex surface-associated proteoglycan (PG) recognized to be widely expressed membrane component of glioblastoma (WHO grade IV) cells and angiogenic pericytes. To determine the precise expression pattern on pericytes, we generated panel >60 mouse monoclonal antibodies (mAbs) directed against ectodomain human NG2/CSPG4, partially characterized mAbs, performed high-resolution distributional mapping PG in foetal, adult glioblastoma-affected brains. The reactivity initially...
Chromogranin A (CgA), a neuroendocrine secretory protein, and its fragments are present in variable amounts the blood of normal subjects cancer patients. We investigated whether circulating CgA has regulatory function tumor biology progression. Systemic administration full-length CgA, but not lacking C-terminal region, could reduce growth murine models fibrosarcoma, mammary adenocarcinoma, Lewis lung carcinoma, primary metastatic melanoma, with U-shaped dose-response curves. Tumor inhibition...
Background Chromogranin A (CgA) is a plasma biomarker widely used in the follow-up of patients with neuroendocrine neoplasms (NENs). However, its accuracy as tumor relatively low because CgA can increase also other diseases or subjects treated proton-pump inhibitors (PPIs), class widely-used drugs. Methods In attempt to identify more reliable for NENs, we investigated, by ELISA, circulating levels full-length (CgA1-439) and various CgA-derived fragments 17 ileal pancreatic 10 healthy...
The unbalanced production of pro- and antiangiogenic factors in tumors can lead to aberrant vasculature morphology, angiogenesis, disease progression. In this study, we report that progression various murine models solid is associated with increased cleavage full-length chromogranin A (CgA), a circulating vasoregulatory neurosecretory protein. Cleavage CgA led the exposure highly conserved PGPQLR site, which corresponds residues 368-373 human CgA1-373, fragment has proangiogenic activity....
Chromogranin A (CgA), a secretory protein released in the blood by neuroendocrine system, consists of mixture full-length molecules and fragments endowed vasoregulatory activity. The extent role CgA fragmentation were investigated patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC, n=172). Multivariate analysis showed that was associated better progression free overall survival, whereas C-terminal worse prognosis. In vitro studies PDAC cells can promote...
<div>Abstract<p>The unbalanced production of pro- and antiangiogenic factors in tumors can lead to aberrant vasculature morphology, angiogenesis, disease progression. In this study, we report that progression various murine models solid is associated with increased cleavage full-length chromogranin A (CgA), a circulating vasoregulatory neurosecretory protein. Cleavage CgA led the exposure highly conserved PGPQLR site, which corresponds residues 368–373 human...
<p>Sup Fig 1: Characterization of mAb 9D1 and its effects on tumor growth NRP1/CgA1-373 interaction; Sup 2: Effect aprotinin treatment CgA cleavage; 3: Anti-PGPQLR monoclonal polyclonal antibodies inhibit in various murine models; 4: anti-PQLR IgGs (highly specific for CgA1-373) anti-QALRRG (C-terminal region CgA1-439) growth; 5: anti-PGPQLR WEHI-164 fibrosarcoma vasculature; 6: CgA1-373 FGF2 HUVEC proliferation; 7: NRP1, but not NRP2, binds CgA1-373; the binding is blocked by or...
<p>Sup Fig 1: Characterization of mAb 9D1 and its effects on tumor growth NRP1/CgA1-373 interaction; Sup 2: Effect aprotinin treatment CgA cleavage; 3: Anti-PGPQLR monoclonal polyclonal antibodies inhibit in various murine models; 4: anti-PQLR IgGs (highly specific for CgA1-373) anti-QALRRG (C-terminal region CgA1-439) growth; 5: anti-PGPQLR WEHI-164 fibrosarcoma vasculature; 6: CgA1-373 FGF2 HUVEC proliferation; 7: NRP1, but not NRP2, binds CgA1-373; the binding is blocked by or...
<div>Abstract<p>The unbalanced production of pro- and antiangiogenic factors in tumors can lead to aberrant vasculature morphology, angiogenesis, disease progression. In this study, we report that progression various murine models solid is associated with increased cleavage full-length chromogranin A (CgA), a circulating vasoregulatory neurosecretory protein. Cleavage CgA led the exposure highly conserved PGPQLR site, which corresponds residues 368–373 human...